{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:08Z","timestamp":1758587948801,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:07:36Z","timestamp":1612530456000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["D\u00e9claration des erreurs m\u00e9dicamenteuses dans les recherches portant sur le m\u00e9dicament\u00a0: place du pharmacien des essais cliniques\u00a0?"],"prefix":"10.1016","volume":"76","author":[{"given":"Elodie","family":"Delavoipi\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Fourage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Olivier-Abbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Mouchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylaure","family":"Gavard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Paule","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Savary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Chaillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Alix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Peyro-Saint-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"Bonnes pratiques de pharmacovigilance","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","key":"10.1016\/j.therap.2021.02.002_bib0140"},{"year":"2009","series-title":"Guichet erreurs m\u00e9dicamenteuses\u00a0: pr\u00e9sentation et bilan depuis la mise en place","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","key":"10.1016\/j.therap.2021.02.002_bib0145"},{"issue":"10","key":"10.1016\/j.therap.2021.02.002_bib0150","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"year":"2011","series-title":"Arr\u00eat\u00e9 du 6\u00a0avril 2011\u00a0relatif au management de la qualit\u00e9 de la prise en charge m\u00e9dicamenteuse et aux m\u00e9dicaments dans les \u00e9tablissements de sant\u00e9. JORFavril","author":"Legifrance","key":"10.1016\/j.therap.2021.02.002_bib0155"},{"year":"2001","series-title":"Bonnes pratiques de pharmacie hospitali\u00e8re\u00a0\u2013\u00a01\u00e8re \u00e9dition","key":"10.1016\/j.therap.2021.02.002_bib0160"},{"issue":"18_suppl","key":"10.1016\/j.therap.2021.02.002_bib0165","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1200\/jco.2007.25.18_suppl.6547","article-title":"Medication safety in cancer clinical trials: an analysis of medication error reports at a comprehensive cancer center","volume":"25","author":"Kane","year":"2007","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.therap.2021.02.002_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1078155219834723","article-title":"Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials","volume":"26","author":"Moon","year":"2020","journal-title":"J Oncol Pharm Pract"},{"year":"2020","series-title":"Guide professionnel\u00a0\u2013\u00a0Activit\u00e9s pharmaceutiques relatives aux essais cliniques de m\u00e9dicaments et de dispositifs m\u00e9dicaux r\u00e9alis\u00e9s au sein des \u00e9tablissements de sant\u00e9","author":"Commission pharmaciens de centres hospitaliers universitaires essais cliniques","key":"10.1016\/j.therap.2021.02.002_bib0175"},{"issue":"3","key":"10.1016\/j.therap.2021.02.002_bib0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/intqhc\/mzw025","article-title":"SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study","volume":"28","author":"Dollinger","year":"2016","journal-title":"Int J Qual Health Care"},{"year":"2018","series-title":"Investigational drugs: product-related issues pose significant challenges (Part I)","author":"ISMP. Institute for Safe Medication Practice","key":"10.1016\/j.therap.2021.02.002_bib0185"},{"issue":"3","key":"10.1016\/j.therap.2021.02.002_bib0190","first-page":"120","article-title":"Reducing the potential for mistakes with investigational drugs","volume":"36","author":"Grissinger","year":"2011","journal-title":"P T"},{"issue":"8","key":"10.1016\/j.therap.2021.02.002_bib0195","doi-asserted-by":"crossref","first-page":"e0220383","DOI":"10.1371\/journal.pone.0220383","article-title":"What do adult outpatients included in clinical trials know about the investigational drugs being assessed: A cross-sectional study in France","volume":"14","author":"Fronteau","year":"2019","journal-title":"PLoS ONE"},{"year":"2014","series-title":"R\u00e8glement (UE) n\u00b0\u00a0536\/2014\u00a0du Parlement europ\u00e9en et du Conseil du 16\u00a0avril 2014\u00a0relatif aux essais cliniques de m\u00e9dicaments \u00e0 usage humain et abrogeant la directive 2001\/20\/CE Texte pr\u00e9sentant de l\u2019int\u00e9r\u00eat pour l\u2019EEE. JOUE","author":"Eur-Lex Europa","key":"10.1016\/j.therap.2021.02.002_bib0200"},{"year":"2012","series-title":"Loi no\u00a02012-300\u00a0du 5\u00a0mars 2012\u00a0relative aux recherches impliquant la personne humaine (1)","author":"Legifrance","key":"10.1016\/j.therap.2021.02.002_bib0205"},{"year":"2006","series-title":"D\u00e9cision du 24\u00a0novembre 2006\u00a0fixant les r\u00e8gles de bonnes pratiques cliniques pour les recherches biom\u00e9dicales portant sur des m\u00e9dicaments \u00e0 usage humain. JORF","author":"L\u00e9gifrance","key":"10.1016\/j.therap.2021.02.002_bib0210"},{"key":"10.1016\/j.therap.2021.02.002_bib0215","series-title":"Journal officiel de l\u2019Union europ\u00e9enne","article-title":"Communication de la Commission\u00a0\u2014\u00a0Indications d\u00e9taill\u00e9es concernant l\u2019\u00e9tablissement, la v\u00e9rification et la pr\u00e9sentation des rapports sur les \u00e9v\u00e9nements\/effets ind\u00e9sirables fond\u00e9s sur des essais cliniques de m\u00e9dicaments \u00e0 usage humain (CT-3)","author":"Commission europ\u00e9enne","year":"2011"},{"year":"2020","series-title":"Avis aux promoteurs d\u2019essais cliniques de m\u00e9dicaments y compris les m\u00e9dicaments de th\u00e9rapie innovante\u00a0\u2013\u00a0Tome II. Vigilance des essais cliniques","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","key":"10.1016\/j.therap.2021.02.002_bib0220"},{"year":"2020","series-title":"MedDRA\u00ae term selection. Points to consider. ICH-endorsed guide for MedDRA users Release 4.19\u00a0\u2013\u00a0Based on MedDRA Version 23.0","author":"MedDRA\u00ae","key":"10.1016\/j.therap.2021.02.002_bib0225"},{"year":"2020","series-title":"MedDRA\u00ae points to consider companion document - ICH-endorsed guide for MedDRA users. Release 1.1","author":"MedDRA\u00ae","key":"10.1016\/j.therap.2021.02.002_bib0230"},{"year":"2016","series-title":"Regional implementation specifications for ICH E2B(R3) implementation: postmarket submission of individual case safety reports for drugs and biologics, excluding vaccines","author":"FDA","key":"10.1016\/j.therap.2021.02.002_bib0235"},{"year":"2017","series-title":"ICH guideline E2B (R3)\u00a0\u2013\u00a0questions and answers. Step 5 [Internet]. Committee for Human Medicinal Products. Report No.: EMA\/CHMP\/ICH\/3943\/2003","author":"European Medicines Agency","key":"10.1016\/j.therap.2021.02.002_bib0240"},{"year":"2017","series-title":"Guideline on good pharmacovigilance practices (GVP) \u2013\u00a0Module VI\u00a0\u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2)","author":"European Medicines Agency","key":"10.1016\/j.therap.2021.02.002_bib0245"},{"year":"2018","series-title":"Guideline on good pharmacovigilance practices (GVP) \u2013\u00a0Product\u00a0\u2013 or population-specific considerations IV: Paediatric population","key":"10.1016\/j.therap.2021.02.002_bib0250"},{"year":"2006","series-title":"Dictionnaire fran\u00e7ais de l\u2019erreur m\u00e9dicamenteuse","author":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie clinique","key":"10.1016\/j.therap.2021.02.002_bib0255"},{"key":"10.1016\/j.therap.2021.02.002_bib0260","unstructured":"Code de la sant\u00e9 publique \u2013\u00a0Article R1123-39\u00a0\u2013 L\u00e9gifrance. 2017. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000033418177\/2017-03-29. [Consult\u00e9 le 19\u00a0janvier 2021]."},{"key":"10.1016\/j.therap.2021.02.002_bib0265","unstructured":"Code de la sant\u00e9 publique \u2013\u00a0Article L5126-1\u00a0\u2013 L\u00e9gifrance. 2020. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000042656015\/2020-12-09. [Consult\u00e9 le 19\u00a0janvier 2021]."},{"issue":"1","key":"10.1016\/j.therap.2021.02.002_bib0135","first-page":"125","article-title":"Medication safety in clinical trials: role of the pharmacist in optimizing practice, collaboration, and education to reduce errors","volume":"90","author":"Brown","year":"2017","journal-title":"Yale J Biol Med"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:56:06Z","timestamp":1758567366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0040595721000706"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9claration des erreurs m\u00e9dicamenteuses dans les recherches portant sur le m\u00e9dicament\u00a0: place du pharmacien des essais cliniques\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}